It is possible that isolated CTLA-4 positive breast cancer cells could have a different responsiveness to ipilimumab or hyperglycemia; further studies will be performed on isolated CTLA-4 + breast cancer cells, studying their metabolism and their responsiveness to glucose and growth factors. Here, CTLA4 is linked to breast carcinoma.